Senator Jaziri Alkaf Abdillah Suffian (left) and Boo during Yong Tai’s virtual signing ceremony.
PETALING JAYA: Yong Tai Bhd has formalised its collaboration with China’s Shenzhen Kangtai Biological Products Co Ltd by entering into a definitive agreement for the Phase III clinical trials and commercialisation of the latter’s Covid-19 vaccine.
This cements the collaboration that was set up with the head of agreement framework signed in December 2020.
Yong Tai CEO Datuk Boo Kuang Loon said the agreement marks another milestone for the group in its foray into the pharmaceutical business and he is confident that the collaboration will bear fruit in the near term based on Shenzhen Kangtai’s track record.
Sri Lanka plans to purchase three million doses of India’s Covishield vaccine and use a combination of Indian, Russian and Chinese-manufactured COVID-19 vaccines pending approval to immunise 50 to 60 per cent of the population within the year, an official said. Presidential advisor Lalith Weeratunga told reporters that Sri Lanka has sent a formal request […]
No influence on NMRA to approve COVID-19 vaccines dailynews.lk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailynews.lk Daily Mail and Mail on Sunday newspapers.
Tharanga Lanka Weerawardana
Alaris Lanka Pvt Ltd conducted a press conference recently to explain to the media regarding the false rumours about their brand “Facia Premium”.
Mr. Tharanga Lanka Weerawardana, Chairman and the Managing Director of Alaris Group of Companies stated that a false letter baring the letterhead of the National Medicine Regulatory Authority and forged signature of Dr. Kamal Jayasinghe who is the CEO of the National Medicines Regulatory Authority stating that the product Facia Premium has been banned has been circulated in some print and social media.
The CEO of NMRA has denied the issuance of such letter and instructed the Director of the Fraud Investigation Bureau to conduct an investigation on priority basis.